Q&A: Using liquid biopsies 
to build CDx in pancreatic cancer with Actuate Therapeutics

Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer.

Jun 28, 2023
Life Sciences
Article
Michael YasiejkoGeneral Manager and Executive Vice President, Tempus
Andrew Mazar, PhDChief Operating Officer, Actuate

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Constructing clinical timelines with line of therapy

Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Light background with faint, pixelated letters resembling DNA or digital code.

Designing smarter trials: A new model for clinical development

2026-04-28
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract image with blurred geometric cubes and DNA sequences on a light background.

How biotechs can build a data-driven R&D strategy

2026-04-27
Life Sciences